BERWYN, Pa.--( BUSINESS WIRE )--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic ® in Ocudose ® ) and has begun commercialization activities. Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to: the preservative in Timolol Maleate Ophthalmic Solution, USP, benzalkonium chloride, or when the use of a preservative-free topical medication is advisable. "We are pleased to have a